CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors
Open Access
- 22 May 2026
- journal article
- review article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Abstract
Glioma is an aggressive brain malignancy characterized by a markedly immunosuppressive microenvironment and limited response to conventional treatments. CDKeywords
Funding Information
- Startup Fund for Advanced Talents of Putian University (2026022)
- Natural Science Foundation of Fujian Province (2026J0011082)
This publication has 128 references indexed in Scilit:
- CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastomaCellular and Molecular Life Sciences, 2023
- Tumor Cell‐Intrinsic CD96 Mediates Chemoresistance and Cancer Stemness by Regulating Mitochondrial Fatty Acid β‐OxidationAdvanced Science, 2022
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent GlioblastomaJAMA Oncology, 2020
- TIGIT enhances CD4+ regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer modelCancer Medicine, 2020
- CD96 functions as a co‐stimulatory receptor to enhance CD8+ T cell activation and effector responsesEuropean Journal of Immunology, 2020
- Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapyJournal of Cellular Physiology, 2018
- An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppressionCancer Immunology, Immunotherapy, 2018
- TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individualsEuropean Journal of Immunology, 2015
- Mouse TIGIT inhibits NK‐cell cytotoxicity upon interaction with PVREuropean Journal of Immunology, 2013
- The poliovirus receptor protein is produced both as membrane‐bound and secreted forms.The EMBO Journal, 1990